Predictors of Long-Term Outcomes of Percutaneous Mitral Valvuloplasty in Patients with Rheumatic Mitral Stenosis

Kim, Darae; Chung, Hyemoon; Nam, Jong-Ho; Park, Dong Hyuk; Shim, Chi Young; Kim, Jung Sun; Chang, Hyuk Jae; Hong, Geu Ru; Ha, Jong Won

doi:10.3349/ymj.2018.59.2.273

Cited by 15 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The present study has addressed an important issue of practical importance in the management of symptomatic severe mitral stenosis in Ethiopian context and yielded an excellent result which is analogues with a number of previous studies done elsewhere that documented satisfactory immediate and long-term outcome [18][19][20][21][22]. The dominant mechanism of commissurotomy is by splitting the commissures and giving non fused, wide open mitral valve [23].…”

Section: Discussionsupporting

confidence: 76%

Immediate Outcome and Predictors of Percutaneous Mitral Balloon Commissurotomy: A 5 Years Experience in Cardiac Center Ethiopia

Sebah¹,

Tadesse²,

Mohammed³

et al. 2019

CCR

View full text Add to dashboard Cite

Percutaneous mitral balloon commissurotomy (PMBC) is the treatment of choice for rheumatic mitral stenosis with favorable anatomy and prevents complications inherent to a surgical procedure, while maintaining effectiveness. In view of this, we examined the immediate outcome and its predictors of patients undergoing PMBC in our Cardiac Center and availed evidence based information for future use of the treatment in Ethiopia. A retrospective data analysis of 330 patients with symptomatic severe mitral stenosis treated with PMBC using Inoue balloon in the cardiac center Ethiopia from 2014 to 2018 were assessed for their clinical outcome for those who presented for the first time in our cardiac center, Addis Ababa. Demographic, clinical, echocardiographic and hemodynamic data of all patients with symptomatic severe mitral stenosis were collected and analyzed. Of the 330 PMBC performed during the 5 years in the center, the majority had successful procedure (97.88%) and optimal result (92.42%). Twenty four (7.2%) had complications of which 7 (2.1%) had failed procedure and 9 (2.7%) marked mitral regurgitation. Atrial fibrillation was observed in 67 (20.3%). The mean mitral valve score (MVS) was 7.3± 1.35 ranged from 4 to 13. A significant association of immediate outcome was observed with atrial fibrillation (AOR=4.41; 95% CI=1.51 to 12.89) and high mitral valve total Wilkins score (AOR=0.25; 95% CI 0.09 to 0.70). The major predictors identified for poor outcome are atrial fibrillation and MVS. Percutaneous mitral balloon commissurotomy is a safe procedure with excellent immediate results signifying that it is a treatment of choice for heterogeneous group of patients with rheumatic mitral stenosis.

show abstract

Section: Discussionsupporting

confidence: 76%

Immediate Outcome and Predictors of Percutaneous Mitral Balloon Commissurotomy: A 5 Years Experience in Cardiac Center Ethiopia

Sebah¹,

Tadesse²,

Mohammed³

et al. 2019

CCR

View full text Add to dashboard Cite

show abstract

“…In total, we identified 3,212 records among which 83 studies were finally included (Supplementary Figure 1) [ 8 9 10 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 ...…”

Section: Resultsmentioning

confidence: 99%

Meta-Analysis of the Incidence, Prevalence, and Correlates of Atrial Fibrillation in Rheumatic Heart Disease

Noubiap

Nyaga²,

Ndoadoumgue

et al. 2020

Global Heart

View full text Add to dashboard Cite

Objective: To estimate the incidence, prevalence, and correlates of atrial fibrillation (AF) in a global population with rheumatic heart disease (RHD). Methods: Bibliographic databases were searched to identify all published studies providing data on AF in patients with RHD. Random-effects meta-analysis method was used to pool estimates. Results: Eighty-three studies were included, reporting data from 75,637 participants with RHD in 42 countries. The global prevalence of AF in RHD was 32.8% (range: 4.3%-79.9%). It was higher in severe valvular disease (30.8% vs 20.7%, p = 0.009), in severe mitral valve disease compared to severe aortic disease (30.4% vs 6.3%, p = 0.038). The global cumulative incidence of AF in patients with RHD was 4.8%, 11.4%, 13.2%, and 30.8% at 1, 2, 5, and 10 years of follow-up, respectively. From comparison between patients with and without AF, AF was associated with increased age (mean difference [MD]: 9.5 years; 95% CI: 7.8-1.3), advanced heart failure (odds ratio [OR]: 4.4; 95% CI 2.1-9.3), tricuspid valve involvement (OR: 4.

show abstract

“…[25] Another study evaluating the immediate results of repeat PBMV and introducing a simplified redo-score to predict the success of repeat PBMV showed that the redo-score system was significantly more predictive than the Wilkins score and was particularly valuable in predicting outcome in patients who underwent PBMV. [26] We used the following methods to prevent systemic embolism:…”

Section: Discussionmentioning

confidence: 99%

Study on the long-term curative effect of repeat percutaneous balloon mitral valvuloplasty in patients with mitral restenosis

Zhang

Hou²,

Duan³

et al. 2019

Medicine

View full text Add to dashboard Cite

To study the long-term curative effect of repeat percutaneous balloon mitral valvuloplasty (PBMV) in patients with mitral restenosis. In our study, mitral restenosis developed in 39 patients after PBMV. Repeat PBMV was performed according to the improved Inoue method. All patients were followed up. Of 39 patients, 36 were successfully treated with repeat PBMV (achievement ratio, 92.3%). Immediately after repeat PBMV, clinical symptoms and left atrial mean pressure (LAP), pulmonary artery systolic pressure (PASP), mitral valve gradient (MVG), and mitral valve orifice area (MVA) improved significantly (24.50 ± 6.54 mmHg vs 9.66 ± 4.21 mmHg for LAP, 1.05 ± 0.19 cm 2 vs 2.23 ± 0.22 cm 2 for MVA, 17.03 ± 4.52 mmHg vs 7.79 ± 4.07 mmHg for MVG, 58.12 ± 12.68 mmHg vs 31.45 ± 10.02 mmHg for PASP; P <.05). Meanwhile, left atrial end-diastolic dimension (LAD) was altered slightly (4.71 ± 0.75 vs 4.07 ± 0.69, P >.05). The 36 patients were followed up for 69 ± 23 (12–146) months. After long-term follow-up immediately after repeat PBMV, the results did not show a significant change (2.23 ± −0.22 cm 2 vs 2.02 ± −0.21 cm 2 for MVA, 7.79 ± −4.07 mmHg vs 9.15 ± -4.11 mmHg for MVG; P >.05) and were approximated to those shortly after repeat PBMV (2.23 ± 0.22 cm 2 vs 2.02 ± 0.21 cm 2 for MVA, 7.79 ± 4.07 mmHg vs 9.15 ± 4.11 mmHg for MVG; P > 0.05). LAD did not change significantly (4.13 ± 0.71 cm vs. 4.07 ± 0.69 cm; P >.05). The long-term follow-up results showed that cardiac function and quality of life were significantly improved in most patients. It would be safe for patients with mitral restenosis to undergo repeat PBMV. Appropriate cases should be selected, and treatment should be performed cautiously. Short- and long-term curative effects would be satisfactory. We suggested that repeat PBMV be the first choice for patients with mitral restenosis after first PBMV.

show abstract

Predictors of Long-Term Outcomes of Percutaneous Mitral Valvuloplasty in Patients with Rheumatic Mitral Stenosis

Cited by 15 publications

References 27 publications

Immediate Outcome and Predictors of Percutaneous Mitral Balloon Commissurotomy: A 5 Years Experience in Cardiac Center Ethiopia

Immediate Outcome and Predictors of Percutaneous Mitral Balloon Commissurotomy: A 5 Years Experience in Cardiac Center Ethiopia

Meta-Analysis of the Incidence, Prevalence, and Correlates of Atrial Fibrillation in Rheumatic Heart Disease

Study on the long-term curative effect of repeat percutaneous balloon mitral valvuloplasty in patients with mitral restenosis

Contact Info

Product

Resources

About